Hanne Mette D. Kristensen is CEO of Targovax AS.
She has a strong track record in commercialization of research and early phase company development. She holds an M.Sc. in biochemistry from the University of Oslo, and an MBA in Technology Management (MTM) from NTNU, NHH and MIT Sloan School of Management.
Before joining Bio-Medical Innovation she was CEO of Diatec Monoclonals for six years, leading the company from a startup phase towards stable and positive cashflow. She was earlier head of product development and production in the same company, establishing a line of cancer diagnostic antibodies, and developing a base of contract research customers. She has also been a scientist at the Institute of Immunology, Oslo University Hospital.